Nanometics LLC
Nanometics is developing nontoxic transition state inhibitors for triple negative breast cancer that work through a novel target
- Stage Product In Development
- Industry Biotechnology
- Location New York City, NY, USA
- Currency USD
- Founded January 2007
- Employees 5
- Website nanometicslab.com
Company Summary
Nanometics is a biotechnology company focused on developing oral medications for diseases with high unmet medical need. The company has received over $3.1 million in NIH funding in the past three years, and focuses on oncology and hematology projects.
Team
Advisors
-
Henry Coleman, Ph.D.LawyerUnconfirmedEric Mendelsohn, CPAAccountantUnconfirmed
Previous Investors
-
National Heart Lung and Blood InstituteUnconfirmedNational Cancer InstituteUnconfirmed
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.